Metabolic changes in breast cancer on dual-time-point 18F-FDG PET/CT imaging according to primary tumor uptake and background parenchymal enhancement

Kim, Hye Ok; Kim, Bom Sahn; Kang, Seo Young; Bang, Ji In; An, Jeongshin; Kim, Jeoung Hyun; Yoon, Hai Jeon

doi:10.1007/s12149-020-01525-z

Cited by 5 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When a 50% dose of FDG was injected, there was no difference in contrast and smoothness between the images scanned from 60 and 90 min after injection. Previous studies using whole-body PET/CT reported that SUVs of breast cancer lesions on images of early scans 60 min after FDG injection were higher than those on images of delayed scans 120 min after injection [ 17 , 18 ]. This is because the contrast between the lesion and the background increases due to the increase in FDG accumulation in breast cancer lesions over time as well as the washout of the physiological accumulation in normal tissues, such as the mammary gland.…”

Section: Discussionmentioning

confidence: 99%

“…This is because the contrast between the lesion and the background increases due to the increase in FDG accumulation in breast cancer lesions over time as well as the washout of the physiological accumulation in normal tissues, such as the mammary gland. The physiological uptake of FDG in the normal mammary gland varies according to the menstrual cycle [ 19 ], and the uptake to the normal mammary gland in the early scans is washed out in the delayed scans, improving the detectability of breast cancer with low FDG uptake [ 17 ]. Since positron-emitting nuclides emit high-energy gamma rays, subjects injected with a PET tracer should wait in a radiation-controlled area until scanning begins.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Image quality evaluation of real low-dose breast PET

Satoh

Imai²,

Ikegawa³

et al. 2022

Jpn J Radiol

View full text Add to dashboard Cite

Purpose To evaluate the clinical feasibility of high-resolution dedicated breast positron emission tomography (dbPET) with real low-dose 18F-2-fluorodeoxy-d-glucose (18F-FDG) by comparing images acquired with full-dose FDG. Materials and methods Nine women with no history of breast cancer and previously scanned by dbPET injected with a clinical 18F-FDG dose (3 MBq/kg) were enrolled. They were injected with 50% of the clinical 18F-FDG dose and scanned with dbPET for 10 min for each breast 60 and 90 min after injection. To investigate the effect of the scan start time and acquisition time on image quality, list-mode data were divided into 1, 3, 5, and 7 min (and 10 min with 50% FDG injected) from the start of acquisition and reconstructed. The reconstructed images were visually and quantitatively compared for contrast between mammary gland and fat (contrast) and for coefficient of variation (CV) in the mammary gland. Results In visual evaluation, the contrast between the mammary gland and fat acquired at a 50% dose for 7 min was comparable and even better in smoothness than that in the images acquired at a 100% dose. No visual difference between the images with a 50% dose was found with scan start times 60 and 90 min after injection. Quantitative evaluation showed a slightly lower contrast in the image at 60 min after 50% dosing, with no difference between acquisition times. There was no difference in CV between conditions; however, smoothness decreased with shorter acquisition time in all conditions. Conclusions The quality of dbPET images with a 50% FDG dose was high enough for clinical application. Although the optimal scan start time for improved lesion-to-background mammary gland contrast remained unknown in this study, it will be clarified in future studies of breast cancer patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Image quality evaluation of real low-dose breast PET

Satoh

Imai²,

Ikegawa³

et al. 2022

Jpn J Radiol

View full text Add to dashboard Cite

show abstract

“…It should be remembered that [ 18 F]F-FDG is not a specific radiotracer for BC or malignancy in general, and numerous conditions may lead to false-positive results, such as infection, fibroadenoma, ductal adenoma, inflammatory granulomatous mastitis, and fibrocystic changes ( 23 – 28 ). Some authors investigated the use of late imaging to improve specificity, since uptake usually increases on delayed images in case of malignancy, while it often decreases in inflammatory lesions ( 29 , 30 ). However, [ 18 F]F-FDG can only provide information on cellular metabolism and not on other tumor characteristics, such as proliferation and receptor status.…”

Section: Molecular Imaging Of Glycolysismentioning

confidence: 99%

Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review

Balma¹,

Liberini

Racca

et al. 2022

Front. Med.

View full text Add to dashboard Cite

Breast cancer is one of the most common malignancies in women, with high morbidity and mortality rates. In breast cancer, the use of novel radiopharmaceuticals in nuclear medicine can improve the accuracy of diagnosis and staging, refine surveillance strategies and accuracy in choosing personalized treatment approaches, including radioligand therapy. Nuclear medicine thus shows great promise for improving the quality of life of breast cancer patients by allowing non-invasive assessment of the diverse and complex biological processes underlying the development of breast cancer and its evolution under therapy. This review aims to describe molecular probes currently in clinical use as well as those under investigation holding great promise for personalized medicine and precision oncology in breast cancer.

show abstract